Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura I Yousif

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
JACC. Cardiooncology|August 21, 2025
Current Insights in Bidirectional Cardio-Oncology: Heart Failure Driving Cancer: JACC: CardioOncology Short-Form PrimerRudolf A de Boer, Laura I Yousif, Joseph Pierre Aboumsallem, et al.
Current Heart Failure Reports|April 7, 2026
TIM-3 in Cardiovascular DiseaseLaura I Yousif, Aukje G Sijtema, Margot J Chevalier, et al.
Frontiers in Pharmacology|October 20, 2022
The role of immune checkpoints in cardiovascular diseaseLaura I Yousif, Anniek A Tanja, Rudolf A de Boer, et al.
Heart, Lung & Circulation|February 12, 2025
Cardiotoxicity Beyond Cardiomyocytes-Focus on the Role of Cardiac Fibroblasts and Endothelial CellsYmke Appels, Laura I Yousif, Charlotte S Pieters, et al.
Current Oncology Reports|April 20, 2023
Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular ToxicitiesLaura I Yousif, Elles M Screever, Daniëlle Versluis, et al.
JACC. Basic to Translational Science|April 19, 2026
PD-1/PD-L1 Signaling in Non-ICI MyocarditisLaura I Yousif, Aukje G Sijtema, Ymke Appels, et al.
JACC. Cardiooncology|August 24, 2023
Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart FailurePieter F van den Berg, Joseph Pierre Aboumsallem, Elles M Screever, et al.
British Journal of Pharmacology|November 10, 2022
Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatmentTamás G Gergely, Dániel Kucsera, Viktória E Tóth, et al.
European Journal of Preventive Cardiology|September 27, 2025
Framingham risk score associates with incident cancer and heart failurePieter F van den Berg, Laura I Yousif, Yvonne Koop, et al.
NPJ Cardiovascular Health|September 22, 2025
The immune checkpoint TIM-3/HMGB-1 axis in myocardial infarctionLaura I Yousif, Aukje G Sijtema, Ymke Appels, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
JACC. Cardiooncology|August 21, 2025
Current Insights in Bidirectional Cardio-Oncology: Heart Failure Driving Cancer: JACC: CardioOncology Short-Form PrimerRudolf A de Boer, Laura I Yousif, Joseph Pierre Aboumsallem, et al.
Current Heart Failure Reports|April 7, 2026
TIM-3 in Cardiovascular DiseaseLaura I Yousif, Aukje G Sijtema, Margot J Chevalier, et al.
Frontiers in Pharmacology|October 20, 2022
The role of immune checkpoints in cardiovascular diseaseLaura I Yousif, Anniek A Tanja, Rudolf A de Boer, et al.
Heart, Lung & Circulation|February 12, 2025
Cardiotoxicity Beyond Cardiomyocytes-Focus on the Role of Cardiac Fibroblasts and Endothelial CellsYmke Appels, Laura I Yousif, Charlotte S Pieters, et al.
Current Oncology Reports|April 20, 2023
Risk Factors for Immune Checkpoint Inhibitor-Mediated Cardiovascular ToxicitiesLaura I Yousif, Elles M Screever, Daniëlle Versluis, et al.
JACC. Basic to Translational Science|April 19, 2026
PD-1/PD-L1 Signaling in Non-ICI MyocarditisLaura I Yousif, Aukje G Sijtema, Ymke Appels, et al.
JACC. Cardiooncology|August 24, 2023
Fibrotic Marker Galectin-3 Identifies Males at Risk of Developing Cancer and Heart FailurePieter F van den Berg, Joseph Pierre Aboumsallem, Elles M Screever, et al.
British Journal of Pharmacology|November 10, 2022
Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatmentTamás G Gergely, Dániel Kucsera, Viktória E Tóth, et al.
European Journal of Preventive Cardiology|September 27, 2025
Framingham risk score associates with incident cancer and heart failurePieter F van den Berg, Laura I Yousif, Yvonne Koop, et al.
NPJ Cardiovascular Health|September 22, 2025
The immune checkpoint TIM-3/HMGB-1 axis in myocardial infarctionLaura I Yousif, Aukje G Sijtema, Ymke Appels, et al.
Pageof 2